Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial-Reference-Cited by-同舟云学术

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

Published:2001-03 Issue:3 Volume:27 Page:493-502
ISSN:0342-4642
Container-title:Intensive Care Medicine
language:en
Short-container-title:Intensive Care Med

Author:

Álvarez-Lerma F.,Insausti-Ordeñana J.,Jordá-Marcos R.,Maraví-Poma E.,Torres-Martí A.,Nava J.,Martínez-Pellús A.,Palomar M.,Barcenilla and the Spanish Collabor F.

Publisher

Springer Science and Business Media LLC

Subject

Critical Care and Intensive Care Medicine

Link

http://link.springer.com/content/pdf/10.1007/s001340000846.pdf

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is There Evidence on the Optimal Duration of Aminoglycoside Therapy in β-Lactam/Aminoglycoside Combination Regimens Used for the Treatment of Gram-Negative Bacterial Infections? A Systematic Review;International Journal of Antimicrobial Agents;2024-10

2. Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis;Annals of Intensive Care;2024-04-25

3. Methods to appraise available evidence and adequacy of data from a systematic literature review to conduct a robust network meta-analysis of treatment options for patients with hospital-acquired or ventilator-associated bacterial pneumonia;PLOS ONE;2023-01-04

4. INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care—study protocol for a multicentre randomised controlled trial;Trials;2021-10-07

5. Comparison of Piperacillin/Tazobactam Dosing (13.5 g/day vs. 18 g/day) for the Treatment of Hospital-Acquired Pneumonia and Ventilator-associated Pneumonia in Intensive Care Unit;Korean Journal of Clinical Pharmacy;2018-09-30